Understanding how cancer cells use exosomes to evade the immune system
Mechanisms of Exosome Driven Immunoregulation of Cancer Progression
This study is looking at how cancer cells use tiny bubbles called exosomes to hide from the immune system, which might help explain why some people respond better to cancer treatments than others, with the hope of creating more personalized therapies for patients.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10381379 on NIH RePORTER |
What this research studies
This research investigates how cancer cells package immune checkpoint proteins into exosomes, which can then suppress the immune response against tumors. By studying the mechanisms behind this process, the research aims to identify why some patients respond well to cancer immunotherapies while others do not. The team of experts will explore the role of exosomal PD-L1 in immune regulation and its impact on T cell function, with the goal of personalizing cancer treatments based on individual responses. Patients may benefit from insights that could lead to more effective therapies tailored to their specific cancer types.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with various types of cancer who are undergoing or considering immunotherapy treatments.
Not a fit: Patients with non-malignant conditions or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments that are more effective for a broader range of patients.
How similar studies have performed: Previous research has shown promising results in understanding immune checkpoint mechanisms, suggesting potential for breakthroughs in cancer treatment.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Blelloch, Robert — University of California, San Francisco
- Study coordinator: Blelloch, Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.